Scarica l'app Stockscreener
4.65
1.69%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.72
Aprire:
$4.77
Volume 24 ore:
605.04K
Relative Volume:
0.84
Capitalizzazione di mercato:
$178.36M
Reddito:
$114.20M
Utile/perdita netta:
$-3.08M
Rapporto P/E:
-11.97
EPS:
-0.3885
Flusso di cassa netto:
$-77.20M
1 W Prestazione:
+10.48%
1M Prestazione:
+49.68%
6M Prestazione:
+16.58%
1 anno Prestazione:
+174.56%
Intervallo 1D:
$4.56
$5.08
Intervallo di 1 settimana:
$3.855
$5.08
Portata 52W:
$1.60
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.645 | 181.24M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
437.99 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.72 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
845.38 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.36 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.26 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Director Harrison of AGENUS INC (AGEN) granted 9,228 shares as board fees - Stock Titan
Agenus (AGEN) price target increased by 25.68% to 15.81 - MSN
Technical Analysis: Should you avoid Agenus Inc stock right nowQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Armen of Agenus (NASDAQ: AGEN) takes salary in stock - Stock Titan
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Buybacks Report: How sensitive is Agenus Inc to inflation2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Setup Watch: Can Agenus Inc deliver consistent EPS growth2026 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Weekly Earnings: Should you avoid Agenus Inc stock right nowPortfolio Performance Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Everything Important About Agenus (AGEN) Receiving a Strong Buy Rating Upgrade - Bitget
Agenus unveils Phase II data for BOT BAL and MiNK iNKT therapy in PD-1 refractory cancer - Traders Union
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy - Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - The AI Journal
HC Wainwright Analysts Boost Earnings Estimates for Agenus - MarketBeat
Has Agenus (AGEN) Surpassed Other Healthcare Stocks So Far This Year? - Bitget
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - 뉴스와이어
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay - Stock Titan
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Portfolio Update: Is Agenus Inc benefiting from interest rate changes2026 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Agenus begins phase 3 trial for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cance - GuruFocus
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cancer Treatment - GuruFocus
Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer - marketscreener.com
Can Agenus' BOT + BAL Immunotherapy Turn Cold Tumors Hot? - RTTNews
Agenus Launches Landmark Global Phase 3 Clinical Trial - Intellectia AI
Agenus begins phase 3 trial for colorectal cancer treatment - Investing.com
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches - MarketBeat
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial. - Bitget
Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.60%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):